$JNJ News

Are You Looking for a High-Growth Dividend Stock?

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Johnson & Johnson Reports Lupus Study Results for Nipocalimab

Johnson & Johnson Reports New Sjögren's Disease Data for Nipocalimab

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic

Is It Too Late To Consider Johnson & Johnson (JNJ) After Its 48% One-Year Surge?

Is Johnson & Johnson (JNJ) One of the Best Dividend Paying Stocks to Buy Right Now?

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

Nanobiotix Equity Raise Backs JNJ-1900 Progress And Volatile Share Rally

Johnson & Johnson (NYSE:JNJ): A Classic Dividend Stock for Sustainable Passive Income

Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

Johnson & Johnson Announces Updated Results From Phase 1/1b CHRYSALIS-2 Study Evaluating Intravenous RYBREVANT In Combination With LAZCLUZE In Patients With Advanced NSCLC With Atypical EGFR Mutations

New TECVAYLI®▼ (teclistamab) data demonstrate superior progression-free and overall survival versus standard of care as early as first relapse in multiple myeloma

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

Johnson & Johnson Announces New Data From Its Phase 3 MajesTEC-9 Study That Show Clinically Meaningful And Statistically Significant Survival Improvements With TECVAYLI In Patients With Relapsed Or Refractory Multiple Myeloma